Articles related to LEUKEMIA

The study’s findings suggest that ibrutinib–venetoclax therapy could potentially revolutionize the treatment of CLL. With a significant reduction in disease progression or death at a median of 43.7 months, this therapy could offer a promising alternative to the standard FCR regimen.

The recent study on FLT3 inhibitor monotherapy brings hope to the field of oncology, particularly for patients with high-risk FLT3-mutated AML. Administered at the stage of molecular failure, the therapy has shown encouraging survival rates.

Discover why CPX-351 extends relapse-free survival but does not significantly alter overall survival in younger AML/MDS patients, as revealed by the UK NCRI AML19 trial.

The recent study on vemurafenib and obinutuzumab offers a promising treatment pathway for previously untreated HCL patients, achieving high rates of complete remission and minimal residual disease negativity.

Discover how base editing via CRISPR-guided cytidine deamination could revolutionize CAR T-cell therapy for T-cell cancers, offering a promising approach to treating relapsed or refractory cases in pediatric patients.

Explore the findings of the A041702 study, presented at the ASCO annual meeting, which investigated the efficacy of two treatment regimens for older patients with CLL. The results, significantly influenced by COVID-19, call for further investigation and long-term follow-up to determine the potential benefits and risks.